The concept of vaccines dates back to1881, when Edward Jenner developed the first vaccine to treat small pox. Since then many technological advancements have been made, in modern times, vaccines have been developed as a new therapeutic for prevention and eradication of cancer. Currently, ranges of therapeutics are available in market to effectually combat cancer, but they suffer from several glitches like low effectiveness and high unspecificity. Researchers came up with the idea of cancer vaccines to alleviate patients suffering from cancer.
Conventionally, vaccines were used for the prevention of contagious diseases, they work by boosting the immune response against the pathogens. Analogously, cancer vaccines work by activating the immune system to attack on cancer cells. Researchers developed cancer vaccines to alleviate patients suffering from cancer. With the technological advances, cancer vaccines have been developed as a new therapeutic for cancer prevention and eradication. Currently, ranges of therapeutics are available in market to effectually combat cancer, but they suffer from several glitches like low effectiveness and high unspecificity.
The cancer vaccines have revolutionized the present views and methodologies of cancer treatment. As a result of which plenty of biotech companies are exploring the field of cancer vaccines. This has caused the development of numerous cancer vaccines for numerous types of cancer. Pharmaceutical companies are using these vaccines for clinical trials; few of them are already available to the patients across the world. The US and EU were the first markets to approve the cancer vaccines for therapeutic usage. As compared to rest of the world, commercialization and development in these regions have already made a significant progress.
The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics.
The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category.
The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years.
“Global Cancer Vaccine Market & Clinical Trial Insight” Report Highlights:
- Global Cancer Market Overview
- Emergence of Personalized Cancer Vaccines
- Platforms for Cancer Vaccines Delivery
- Mechanism of Cancer Vaccines
- Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
- Global Cancer Vaccine Clinical Pipeline: 298 Vaccines
- Marketed Cancer Vaccines: 15 Vaccines
- Regulatory Framework for Cancer Vaccines Development & Marketing